{
    "clinical_study": {
        "@rank": "35333", 
        "arm_group": [
            {
                "arm_group_label": "Magnesium sulfate", 
                "arm_group_type": "Experimental", 
                "description": "Magnesium sulfate. Single dose intravenous over one hour."
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Treatment will be delivered to enrolled patients as currently practice in PEC (Epinephrine nebulization +5%hypertonic saline with/without dexamethasone).\n\u2022All patients will be randomized to receive either Magnesium sulfate over 1 hour or placebo.\u2022Bronchiolitis severity score (BSS) will be recorded at 0, 4, 8, 12, 16,20,24,36,48,60,72 hours, and on discharge."
            }
        ], 
        "brief_summary": {
            "textblock": "In this study, investigators will compare the efficacy and safety of intravenous (IV)\n      Magnesium sulfate in decreasing bronchiolitis clinical severity score and the duration of\n      hospitalization in admitted patients, as compared to placebo."
        }, 
        "brief_title": "Efficacy of Magnesium Sulfate in the Treatment of Bronchiolitis", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Bronchiolitis", 
            "Magnesium, Abnormal Blood Level"
        ], 
        "condition_browse": {
            "mesh_term": "Bronchiolitis"
        }, 
        "detailed_description": {
            "textblock": "-  On arrival to Pediatric Emergency Center, patients will be attended by a pediatric\n           specialist on call who will take history and perform full physical examination.\n           Patients will be assessed for eligibility to the study based on the  inclusion\n           criteria.\n\n        -  Guardians of eligible patients will be approached with the study design, objectives and\n           risks; Patients will be included after obtaining a verbal and assigned written consent.\n\n        -  A chest radiograph and Magnesium level in serum will be requested for all study\n           patients upon recruitment.\n\n        -  The observation physician will complete the data collection sheet that will include the\n           patient's demographics, physical examination, bronchiolitis clinical severity\n           score,oxygen saturation, chest radiograph findings and Magnesium level.\n\n        -  Treatment will be delivered to enrolled patients as currently practice in PEC(Nebulized\n           epinephrine 1:1000  1ml in 5 ml of 5% hypertonic saline, every 4 hours until discharge,\n           for all patients and if there is history of Bronchial Asthma in mother, father or full\n           sibling. And/or history of Eczema in the Child ,patients will start on dexamethasone\n           1mg/kg orally stat.(max-10 mg/dose).   Then 0,6 mg/kg orally once daily starting from\n           second  day of admission for 4 days).\n\n        -  All patients will be randomized to receive either Magnesium sulfate intravenous single\n           dose  over 1 hour or placebo. And it will be given in the same time with currently\n           practice treatment\n\n        -  Epinephrine nebulization can be given on PRN basis up to a maximum of every one hour,\n           at a dose of 0.5 mg/kg (min 2.5mg/dose and max 5 mg/dose) mixed in 5 ml of 5%\n           hypertonic saline.\u2022\n\n        -  Bronchiolitis severity score (BSS) will be recorded at 0, 4, 8, 12,\n           16,20,24,36,48,60,72 hours, and on discharge.\n\n        -  Vital signs will be recorded at 0, 2, 4 hours and then every 4 hours from the\n           administration of study medication.\n\n        -  All patients will be followed up for two weeks post discharge by a phone call asking\n           about the general condition, relapse of symptoms, or need for readmission."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Infants 1-18 months of age presenting to Al Saad Pediatric Emergency Center from October\n        2012 to May 2015  with diagnosis of Bronchiolitis and bronchiolitis clinical severity\n        score > 4,will be include in the study.\n\n        Exclusion Criteria:\n\n          -  Prematurity (Gestational age 34 weeks or less);\n\n          -  Previous history of wheezing;\n\n          -  Use of steroid within 48 hours of presentation;\n\n          -  CRITICALLY ill patients with one or more of the following:\n\n               1. obtunded consciousness\n\n               2. progressive respiratory failure requiring intensive care unit (PICU) admission;\n\n               3. history of apnea within 24 hours before presentation\n\n               4. oxygen saturation < 85% on room air at the time of recruitment\n\n          -  History of chronic lung disease;Chronic lung disease of prematurity Cystic fibrosis;\n\n          -  Congenital heart disease.\n\n          -  All immunodeficient children: primary or secondary\n\n          -  Known hypersensitivity to magnesium sulfate.\n\n          -  Known to have magnesium or calcium metabolism disturbance. (e.g.; vitamin D\n             deficiency, hypoparathyroidism)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "18 Months", 
            "minimum_age": "1 Month"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02145520", 
            "org_study_id": "12216/12", 
            "secondary_id": "12216/12"
        }, 
        "intervention": [
            {
                "arm_group_label": "Magnesium sulfate", 
                "description": "The use of magnesium sulfate intravenous in patient with bronchiolitis in pediatric emergency; follow Broncholitis severity score and length of stay", 
                "intervention_name": "Magnesium Sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "use of placebo with standard therapy", 
                "intervention_name": "placebo", 
                "intervention_type": "Other", 
                "other_name": "normal saline for intravenous."
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Magnesium Sulfate"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "bronchiolitis", 
        "lastchanged_date": "May 22, 2014", 
        "location": {
            "contact": {
                "email": "rafahsayyed@yahoo.com", 
                "last_name": "Rafah F Sayyed, MD", 
                "phone": "+97444396066"
            }, 
            "facility": {
                "address": {
                    "city": "Doha", 
                    "country": "Qatar", 
                    "zip": "465934"
                }, 
                "name": "Pediatric Emergency Center, Al Saad"
            }, 
            "investigator": {
                "last_name": "Rafah F Sayyed, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Qatar"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy of Magnesium Sulfate in the Treatment of Bronchiolitis.", 
        "overall_contact": {
            "email": "kalansari1@hmc.org.qa", 
            "last_name": "Khalid M Al-Ansari, MD", 
            "phone": "+97444396001"
        }, 
        "overall_contact_backup": {
            "email": "rafahsayyed@yahoo.com", 
            "last_name": "Rafah F Sayyed, MD", 
            "phone": "+97444396066"
        }, 
        "overall_official": [
            {
                "affiliation": "HMC", 
                "last_name": "Khalid M Al-Ansai, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "HMC", 
                "last_name": "Rafah F Sayyed, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Qatar: Hamad Medical Corporation", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Would the use of single dose of IV Magnesium sulfate improve percentage of discharge from observation room at 18 hour in patients with moderate to severe broncholitis treated with our bronchiolitis management protocol compared to placebo?", 
            "measure": "Improvement Percentage of Discharge After a Dose of IV Magnesium sulfate", 
            "safety_issue": "Yes", 
            "time_frame": "18 Hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02145520"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Would the use of single dose of IV Magnesium sulfate improve percentage of discharge from observation room at 24,36 ,48 hours and overall length of stay, in patients with moderate to severe bronchiolitis treated with our bronchiolitis management protocol compared to placebo?\nWould the use of IV Magnesium sulfate improve bronchiolitis clinical severity score at 4,8,12,16,20,24,36, 48,72 hours, compared to placebo?\nWould the use of IV Magnesium sulfate decrease the rate of intensive care unit admissions?\nWould the use of IV Magnesium sulfate decrease the need for readmission in follow up?\nWould the use of IV Magnesium sulfate decrease the need for revisit to any medical facility?", 
            "measure": "Improvement of bronchiolitis clinical severity score        48,72 hours", 
            "safety_issue": "Yes", 
            "time_frame": "72 Hours"
        }, 
        "source": "Hamad Medical Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hamad Medical Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}